Literature DB >> 2794785

Effect of a neutralizing monoclonal antibody to cholesteryl ester transfer protein on the redistribution of apolipoproteins A-IV and E among human lipoproteins.

C L Bisgaier1, M V Siebenkas, C B Hesler, T L Swenson, C B Blum, Y L Marcel, R W Milne, R M Glickman, A R Tall.   

Abstract

The effect of inhibiting cholesteryl ester transfer protein (CETP) on the in vitro redistribution of apolipoproteins(apo) A-IV and apoE among lipoproteins in whole plasma was studied in seven normal male subjects. Plasmas were incubated in the presence of a purified monoclonal antibody TP2 (Mab TP2) that neutralizes the activity of CETP. Mab TP2 had no effect on lecithin:cholesterol acyltransferase (LCAT) activity. Prior to and following a 6-h incubation at 37 degrees C in the presence of Mab TP2 or a control mouse myeloma immunoglobulin (IgG), plasmas were gel-filtered on Sephacryl S-300 and the distribution of apoA-IV and apoE among lipoproteins was determined by radioimmunoassay. Incubation (i.e., with active LCAT and CETP) increased the amount of apoA-IV associated with lipoproteins by 240%. When CETP activity was inhibited during incubation, the amount of apoA-IV that became lipoprotein-associated was significantly increased (315% of basal). Plasma incubation also caused a redistribution of apoE from high density lipoproteins (HDL) to larger lipoproteins (131% of basal); however, when CETP was inhibited, significantly greater amounts of apoE became associated with the larger particles (155% of basal). These effects were observed in all seven subjects. Increased movement of apoE from HDL to triglyceride-rich particles was not due to displacement by apoA-IV since loss of apoE from HDL was still observed when no movement of apoA-IV onto HDL occurred, such as during LCAT or combined LCAT and CETP inhibition. We speculate that low CETP activity (e.g., in species such as rats) may lead to an increased content of HDL apoA-IV and also to apoE enrichment of triglyceride-rich lipoproteins, augmenting their clearance.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2794785

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  6 in total

Review 1.  Vaccines for cholesterol management.

Authors:  Charles W Rittershaus
Journal:  World J Surg       Date:  2007-04       Impact factor: 3.352

2.  Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency.

Authors:  S Yamashita; D L Sprecher; N Sakai; Y Matsuzawa; S Tarui; D Y Hui
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

3.  Plasma lipid transfer protein as a determinant of the atherogenicity of monkey plasma lipoproteins.

Authors:  E Quinet; A Tall; R Ramakrishnan; L Rudel
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

4.  Rapid in vivo transport and catabolism of human apolipoprotein A-IV-1 and slower catabolism of the apoA-IV-2 isoprotein.

Authors:  D J Rader; J Schäfer; P Lohse; B Verges; M Kindt; L A Zech; A Steinmetz; H B Brewer
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

5.  Cholesteryl ester transfer protein inhibition in hypercholesterolemic hamsters: kinetics of apoprotein changes.

Authors:  S H Zuckerman; G F Evans
Journal:  Lipids       Date:  1995-04       Impact factor: 1.880

6.  Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E.

Authors:  John S Millar; Michael E Lassman; Tiffany Thomas; Rajasekhar Ramakrishnan; Patricia Jumes; Richard L Dunbar; Emil M deGoma; Amanda L Baer; Wahida Karmally; Daniel S Donovan; Hashmi Rafeek; John A Wagner; Stephen Holleran; Joseph Obunike; Yang Liu; Soumia Aoujil; Taylor Standiford; David E Gutstein; Henry N Ginsberg; Daniel J Rader; Gissette Reyes-Soffer
Journal:  J Lipid Res       Date:  2017-03-17       Impact factor: 5.922

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.